Combining new wearable technology and artificial intelligence, researchers are better able to track motion and monitor the progression of movement disorders.
Biohaven Pharma (BHVN) Phase 3 Clinical Trial Evaluating Troriluzole for Spinocerebellar Ataxia Did Not Reach Statistical Significance streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Friedreich's Ataxia Center of Excellence at CHOP Awarded $1.275 Million to Advance Medical Research miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.